Perivascular cells in diffuse cutaneous systemic sclerosis overexpress activated ADAM12 and are involved in myofibroblast transdifferentiation and development of fibrosis by Cipriani, P. et al.
The Journal of Rheumatology 
Development of Fibrosis
Activated ADAM12 and Are Involved in Myofibroblast Transdifferentiation and 
Perivascular Cells in Diffuse Cutaneous Systemic Sclerosis Overexpress
Alesse, Giovanni Triolo and Roberto Giacomelli
Francesco Carubbi, Francesco Ciccia, Giuliana Guggino, Francesca Zazzeroni, Edoardo 
Paola Cipriani, Paola Di Benedetto, Piero Ruscitti, Vasiliki Liakouli, Onorina Berardicurti,
 http://www.jrheum.org/content/early/2016/05/26/jrheum.150996
DOI: 10.3899/jrheum.150996
 http://www.jrheum.org/cgi/alerts/etoc   
1. Sign up for our monthly e-table of contents 
 http://jrheum.com/subscribe.html   
2. Information on Subscriptions 
 Refer_your_library@jrheum.com   
3. Have us contact your library about access options 
 http://jrheum.com/reprints.html   
4. Information on permissions/orders of reprints 
in rheumatology and related fields. 
Silverman featuring research articles on clinical subjects from scientists working 
 is a monthly international serial edited by Earl D.The Journal of Rheumatology
 Rheumatology
The Journal of on June 5, 2016 - Published by www.jrheum.orgDownloaded from 
1Cipriani, et al: ADAM12 in SSc
Personal non-commercial use only. The Journal of Rheumatology Copyright © 2016. All rights reserved.
Perivascular Cells in Diffuse Cutaneous Systemic
Sclerosis Overexpress Activated ADAM12 and Are
Involved in Myofibroblast Transdifferentiation and
Development of Fibrosis
Paola Cipriani, Paola Di Benedetto, Piero Ruscitti, Vasiliki Liakouli, Onorina Berardicurti,
Francesco Carubbi, Francesco Ciccia, Giuliana Guggino, Francesca Zazzeroni, Edoardo Alesse,
Giovanni Triolo, and Roberto Giacomelli
ABSTRACT. Objective. Microvascular damage is pivotal in the pathogenesis of systemic sclerosis (SSc), preceding
fibrosis, and whose trigger is not still fully understood. Perivascular progenitor cells, with profibrotic
activity and function, are identified by the expression of the isoform 12 of ADAM (ADAM12) and
this molecule may be upregulated by transforming growth factor-β (TGF-β). The goal of this work
was to evaluate whether pericytes in the skin of patients with diffuse cutaneous SSc (dcSSc) expressed
ADAM12, suggesting their potential contribution to the fibrotic process, and whether TGF-β might
modulate this molecule.
Methods. After ethical approval, mesenchymal stem cells (MSC) and fibroblasts (FB) were isolated
from bone marrow and skin samples collected from 20 patients with dcSSc. ADAM12 expression
was investigated in the skin and in isolated MSC and FB treated with TGF-β by immunofluorescence,
quantitative real-time PCR, and western blot. Further, we silenced ADAM12 expression in both
dcSSc-MSC and -FB to confirm the TGF-β modulation.
Results. Pericytes and FB of dcSSc skin showed an increased expression of ADAM12 when compared
with healthy control skin. TGF-β in vitro treatment induced a significant increase of ADAM12 in
both SSc-MSC and -FB, with the higher levels observed in dcSSc cells. After ADAM12 silencing,
the TGF-β ability to upregulate α-smooth muscle actin in both SSc-MSC and SSc-FB was inhibited. 
Conclusion. Our results suggest that in SSc, pericytes that transdifferentiate toward activated FB are
present in the vascular tree, and TGF-β, while increasing ADAM12 expression, may modulate this
transdifferentiation. (J Rheumatol First Release June 1 2016; doi:10.3899/jrheum.150996)
Key Indexing Terms:
SYSTEMIC SCLEROSIS                                          PERICYTE                                          FIBROSIS
From the Department of Applied Clinical Sciences and Biotechnology,
Rheumatology Unit, School of Medicine, and the Department of Applied
Clinical Sciences and Biotechnology, General Pathology Unit, University
of L’Aquila, L’Aquila; Dipartimento Biomedico di Medicina Interna e
Specialistica, Sezione di Reumatologia, Università degli Studi di Palermo,
Palermo, Italy.
P. Cipriani, MD, PhD, Department of Applied Clinical Sciences and
Biotechnology, Rheumatology Unit, School of Medicine, University of
L’Aquila; P. Di Benedetto, PhD, Department of Applied Clinical Sciences
and Biotechnology, Rheumatology Unit, School of Medicine, University of
L’Aquila; P. Ruscitti, MD, Department of Applied Clinical Sciences and
Biotechnology, Rheumatology Unit, School of Medicine, University of
L’Aquila; V. Liakouli, MD, PhD, Department of Applied Clinical Sciences
and Biotechnology, Rheumatology Unit, School of Medicine, University of
L’Aquila; O. Berardicurti, MD, Department of Applied Clinical Sciences
and Biotechnology, Rheumatology Unit, School of Medicine, University of
L’Aquila; F. Carubbi, MD, Department of Applied Clinical Sciences and
Biotechnology, Rheumatology Unit, School of Medicine, University of
L’Aquila; F. Ciccia, MD, PhD, Dipartimento Biomedico di Medicina
Interna e Specialistica, Sezione di Reumatologia, Università degli Studi di
Palermo; G. Guggino, MD, Dipartimento Biomedico di Medicina Interna
e Specialistica, Sezione di Reumatologia, Università degli Studi di
Palermo; F. Zazzeroni, PhD, Department of Applied Clinical Sciences and
Biotechnology, General Pathology Unit, University of L’Aquila; E. Alesse,
MD, PhD, Department of Applied Clinical Sciences and Biotechnology,
General Pathology Unit, University of L’Aquila; G. Triolo, MD, PhD,
Dipartimento Biomedico di Medicina Interna e Specialistica, Sezione di
Reumatologia, Università degli Studi di Palermo; R. Giacomelli, MD,
PhD, Department of Applied Clinical Sciences and Biotechnology,
Rheumatology Unit, School of Medicine, University of L’Aquila.
Address correspondence to Dr. P. Cipriani, Department of Applied
Clinical Sciences and Biotechnology, Rheumatology Unit, School of
Medicine, University of L’Aquila, Delta 6 Building, Via dell’Ospedale,
67100 L’Aquila, Italy. E-mail: paola.cipriani@cc.univaq.it
Accepted for publication April 8, 2016.
Fibrosis may be considered the hallmark of systemic sclerosis
(SSc), affecting not only the skin but also different internal
organs1. In this setting, fibrosis represents the irreversible end
stage triggered by different pathological events inducing
activation and proliferation of resident fibroblasts (FB)
associated with  abnormal myofibroblast recruitment and
proliferation, resulting in increased collagen deposition and
leading to progressive organ dysfunction2,3,4,5.
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During normal conditions, myofibroblasts, characterized
by the presence of stress fibers containing α-smooth muscle
actin (α-SMA), are involved in extracellular matrix (ECM)
deposition and wound contraction during wound healing6,7.
Of note, when compared with normal skin, SSc skin shows a
significant increase in myofibroblasts. The origin of activated
myofibroblasts in the skin of patients with SSc is still a matter
of debate8,9,10,11. There is evidence that activated myofibro -
blasts may arise from local conversion of dermal FB and it is
also possible that resident and circulating mesenchymal
progenitors may transdifferentiate toward activated myofi-
broblasts12,13. Finally, we demonstrated that SSc-endothelial
cells (SSc-EC), under the synergistic effect of transforming
growth factor-β (TGF-β) and endothelin 1, may further trans-
differentiate toward myofibroblasts14.
It has been suggested that pericytes and perivascular
progenitor cells are involved in the process that, starting from
chronic microvascular damage, evolves to fibrosis15,16,17,18.
In fact, lineage tracing experiments, in an experimental model
of kidney fibrosis19, confirmed that these cells are the main
source of myofibroblasts, and the perivascular progenitor
cells, with a profibrotic function, may be identified by the
expression of 1 specific marker, the isoform 12 of ADAM
(ADAM12)20. It is well known that the main expression of
ADAM12 may be observed during embryonic morpho-
genesis of skeletal muscles and visceral organs, and intrigu-
ingly this molecule may be newly expressed in several human
fibrotic diseases21,22,23,24,25,26. Previously, we showed that
because mesenchymal progenitors, which are generally
considered an alternative source of functional pericytes27,28,
exhibit the same phenotype and ability to differentiate of
mature pericytes obtained from patients with SSc, they are
involved in the generation of myofibroblasts in this
disease3,4,5,14.
Translating the results obtained in experimental fibrosis,
in our paper we assessed the expression of ADAM12 on the
perivascular cells in the skin of patients with dcSSc and the
ability of TGF-β, the pivotal profibrotic cytokine in SSc, to
modulate this expression. The evidence of an increased
ADAM12 expression on pericytes, positively modulated by
TGF-β, supports the hypothesis that pericytes, which already
transdifferentiate toward activated myofibroblasts, are
present in the skin of patients with SSc and that these cells,
mirroring other models of fibrosis, may contribute to the FB
accumulation in the fibrotic skin of these patients.
MATERIALS AND METHODS
Patients, controls, and skin biopsies. Full-thickness biopsy samples, 2 × 0.5
cm, isolated from excisional biopsy, were obtained from clinically involved
skin of one-third of the distal forearm of 20 patients with dcSSc according
to LeRoy, et al29. All patients fulfilled the 2013 American College of
Rheumatology/European League Against Rheumatism classification criteria
for SSc30. Skin with a modified Rodnan skin score31 of ≥ 1 was considered
clinically involved.
Of our patients, 50% were in a very early phase of SSc, considering that
the term early, at present, refers to an undifferentiated connective tissue
disease at higher risk to develop SSc, rather than a time at the beginning of
the disease, as suggested by the pivotal study by Koenig, et al32. We further
divided our patients into 2 subsets: patients fulfilling the classification
criteria in < 1 year from the onset of Raynaud phenomenon [early-onset
subset (EOS), n = 10], and all the others [longstanding subset (LSS), n =
10]. Skin samples from the same region of 10 age- and sex-matched healthy
controls (HC) who underwent surgical treatment for trauma were used as
controls. The skin samples were processed for immunofluorescence (IF) and
FB cell isolation and culture. All patients with SSc underwent a 20-day
washout from any immunosuppressive treatment and 1 month from intra-
venous prostanoids before performing skin biopsy. During this period, only
proton-pump inhibitors and clebopride were allowed. Patients who could
not undergo therapeutic washout because of severe organ complications were
not enrolled in our study. Biopsies were taken after informed consent, and
the study was approved by our local committee. Demographic and clinical
characteristics of the patients are shown in Table 1. For IF, the specimens
were fixed in 10% buffered formalin, dehydrated in graded alcohol series,
and embedded in paraffin.
Immunofluorescence. The IF analysis was performed on paraffin sections
(3-µm thickness) using an anti-ADAM12 antibody (Novus). Antigen
retrieval was carried out using Target Retrieval Solution (Dako). The
immunoreaction was revealed using a secondary antibody (Alexa fluor 488,
Sigma-Aldrich). Negative controls were obtained by omitting the primary
antibody. Vasculature pericytes were highlighted using a Cy3 conjugated
mouse monoclonal anti-α-SMA antibody (Sigma-Aldrich) and an unconju-
gated anti-NG2 antibody (Santa Cruz, Biotechnology), EC using unconju-
gated anti-von Willebrand factor antibody (Dako), and FB using
unconjugated anti-S100A4 antibody (Dako). The immunoreaction was
revealed using a secondary antibody (Alexa fluor 555, Sigma-Aldrich). Cell
nuclei were visualized using 4ʹ, 6-diamidino-2-phenylindole. Fluorescence
was analyzed using an Olympus BX53 fluorescence microscope. The
intensity of fluorescence was measured using ImageJ software [US National
Institutes of Health (NIH)]. The median cell count was evaluated by counting
the number of S100A4+/ADAM12+ cells in 5 different high power fields
(40×).
Isolation, culture, and immunophenotyping of MSC. After approval from the
local ethics committee and written informed consent from patients, the bone
marrow was obtained by aspiration from the posterior superior iliac crest
from the patients enrolled in our study. Samples of MSC from bone marrow
donors were used as controls.
MSC were obtained and expanded as previously described3.
Third-passage MSC were analyzed for the surface expression of MSC
antigens (CD45, CD73, CD90, CD34, CD79a, PDGFR-β) and pericyte
markers (α-SMA, SM22α, NG2, desmin, RGS5), as previously described3
(data not shown).
FB isolation and culture. The skin specimen was placed into a 50-ml tube
containing 10 ml of collagenase (Sigma) at 37ºC for 2 h. After digestion, the
samples were cultured in Dulbecco modified Eagle’s medium (Sigma)
supplemented with 10% fetal bovine serum (FBS; Standard South America
origin), 100 units/ml penicillin, and 100 ng/ml streptomycin (Sigma) at 37ºC
in a humidified atmosphere of 5% CO2. The isolated cells were analyzed for
the surface expression of S100A4 antigen by flow cytometry (FACScan,
Becton Dickinson) to assess their purity (S100A4+ cells > 99%).
MSC and FB treatment with TGF-β. The optimal concentration of TGF-β
(R&D) was established with a dose/response curve evaluating ADAM12
mRNA expression in both MSC and FB after TGF-β administration for 7
days. The curve was performed using the MSC of 3 HC. Each experiment
was performed in triplicate. The optimal stimulation dose for TGF-β was 10
ng/ml (data not shown). Both dcSSc and HC cells were cultured for 7 days
in 1% FBS medium supplemented with optimal dose of TGF-β. Medium
was changed every 2 days.
Small interfering RNA (siRNA) assay. dcSSc-MSC were seeded 24 h prior
to transfection. At 70% confluence, the cells were transfected with ADAM12
siRNA (Life Technologies) or with Negative Control no-targeting scrambled
2 The Journal of Rheumatology 2016; 43:7; doi:10.3899/jrheum.150996
Personal non-commercial use only. The Journal of Rheumatology Copyright © 2016. All rights reserved.
 Rheumatology
The Journal of on June 5, 2016 - Published by www.jrheum.orgDownloaded from 
siRNA (scr; Life Technologies) using Lipofectamine 2000 reagent (Life
Technologies). MSC were transfected for 24 h with 50 pmol of siRNA in 2
ml of OptiMem. After incubation, cells were allowed to recover in normal
growth conditions for 24 h post-transfection.
dcSSc-FB were transfected with the same siRNA construct used for
MSC, and the transfection was performed using Lipofectamine 3000 (Life
Technologies). Briefly, FB were plated 24 h prior to transfection. At 70%
confluence, the cells were transfected for 24 h with 25 pmol of siRNA in 2
ml of OptiMem. After incubation, cells were allowed to recover in normal
growth conditions for 24 h post-transfection. The expression of ADAM12
was determined by quantitative real-time PCR (qRT-PCR).
Western blot. MSC and FB, before and after TGF-β treatment, were pelleted,
washed twice with phosphate buffered saline, lysed in lysis buffer (1% Triton
X-100, 0.5% NP-40, 50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 1 mM EDTA,
supplemented with 1 mM phenylmethylsulfonyl fluoride, 1 mM NaF, 1 mM
Na3VO4, 5 μg/ml aprotinin, 5 µg/ml leupeptin) for 30 min and cleared by
centrifugation. The protein concentration was calculated by Bradford protein
assay reagent (Bio-Rad). Fifty micrograms of proteins were separated by
sodium dodecyl sulfate-polyacrylamide gel and transferred to nitrocellulose
membranes. After 1 h blocking at room temperature in blocking buffer [5%
non-fat milk in Tris-buffered saline/1% tween 20 (TBS/T)] and after washing
3 times for 5 min each in TBS/T, the membranes were incubated overnight
at 4°C with the primary antibodies α-SMA (Abcam) and ADAM12 antibody
(Novus) diluted in 5% bovine serum albumin in TBS/T. Following 3 washes
with TBS/T, horseradish peroxidase-conjugated secondary antibodies (Santa
Cruz Biotechnology) diluted in blocking buffer were added for 30 min at
room temperature and washed 3 times with TBS/T. The detection was
performed by enhanced chemiluminescence detection reaction (Amersham
Pharmacia Biotechnology). All the signals were quantified by normalizing
to the tubulin signal (CP06 Anti-α-Tubulin Mouse mAb-DM1A). Immuno -
reactive bands were quantified with densitometry using ImageJ software
(NIH).
qRT-PCR analysis. Total RNA was extracted from TGF-β–treated and 
-untreated MSC and FB using TRIzol (Sigma) and reverse transcribed into
complementary DNA with the ThermoScript reverse transcription–PCR
system (Invitrogen). The qRT-PCR was run in triplicate. ADAM12 and
GAPDH gene expression were assessed by commercial Taqman gene
expression assay (Hs01106101 and Hs02758991, respectively). Col1A1,
α-SMA, and CTGF gene expression was performed using SYBR green kits
(Applied Biosystems). Primers were designed on the basis of the reported
sequences [Primer bank from the National Center for Biotechnology
Information: β-actin: 5ʹ-CCT GGC ACC CAG CAC AAT-3ʹ (forward) and
5ʹ-AGT ACT CCG TGT GGA TCG GC-3ʹ (reverse); α-SMA: 5ʹ-CGG TGC
TGT CTC TCT ATG CC-3ʹ (forward) and 5ʹ-CGC TCA GTC AGG ATC
TTC A-3ʹ (reverse); Col1A1: 5ʹ-AGG GCC AAG ACG AAG ACA GT-3ʹ
(forward) and 5ʹ-AGA TCA CGT CAT CGC ACA ACA-3ʹ (reverse); CTGF:
5ʹ-CAG CAT GGA CGT TCG TCT G-3ʹ (forward) and 5ʹ-AAC CAC GGT
TTG GTC CTT GG-3ʹ (reverse)]. Results were analyzed after 45 cycles of
amplification using the ABI 7500 Fast Real Time PCR System.
Statistical analysis. GraphPad Prism 5.0 software were used for statistical
analyses. Results are expressed as median (range). Because of the nonpara-
metric distribution of our data, the Mann-Whitney U test was used as appro-
priate for analyses. Statistical significance was expressed by a p value < 0.05.
RESULTS
ADAM12 expression in skin dcSSc. Figure 1 shows that
ADAM12 expression in dcSSc skin was significantly higher
when compared with HC skin. Further, in LSS dcSSc skin,
the fluorescence intensity of ADAM12 expression evaluated
using ImageJ was higher than that observed in EOS (Figure
1: B1–6, C1–6, and D).
ADAM12 was strongly expressed in pericytes, EC, and
FB of dcSSc skin. A weak positivity of this molecule was
observed in the same cells of HC skin.
In dcSSc skin, the number of S100A4+/ADAM12+ FB
surrounding the vessels was significantly higher than in HC
3Cipriani, et al: ADAM12 in SSc
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Table 1. Clinical and demographic features of the 20 patients with dcSSc. The internal organ involvement refers to the time of the biopsies.
Sex/Age, Yr of SSc Onset/disease mRSS/score Autoantibodies Lung Involvment, Heart Involvement/ Raynaud 
Yrs Duration at Skin Biopsy at Skin Biopsy HRCT/PFT scleroderma Renal Crisis Phenomenon/
digital Ulcers
F/45 2012/1 10/2 ANA/Scl-70 Normal/normal Normal/no Yes/no
F/22 2013/1 13/1 ANA/Scl-70 Normal/normal Normal/no Yes/yes
F/31 2014/1 08/2 ANA/Scl-70 Normal/normal Normal/no Yes/no
F/38 2012/1 09/2 ANA/Scl-70 Normal/normal PAH/no Yes/yes
M/20 2012/1 11/1 ANA/Scl-70 Normal/normal Normal/no Yes/no
F/40 2012/1 10/2 ANA/Scl-70 Normal/normal Normal/no Yes/no
F/31 2013/1 10/1 ANA/Scl-70 Normal/normal Normal/no Yes/no
F/21 2014/1 09/1 ANA/Scl-70 Normal/normal Normal/no Yes/no
F/31 2012/1 14/1 ANA/Scl-70 Normal/normal Normal/no Yes/no
F/42 2014/1 16/2 ANA/Scl-70 Fibrosis/normal Normal/no Yes/no
F/45 2010/4 17/2 ANA/Scl-70 Normal/normal Normal/no Yes/no
F/21 2009/5 15/1 ANA/Scl-70 Normal/normal Normal/no Yes/no
F/30 2008/6 18/2 ANA/Scl-70 Normal/normal PAH/no Yes/yes
F/33 2010/4 13/2 ANA/Scl-70 Fibrosis/normal Normal/no Yes/no
F/34 2010/4 12/1 ANA/Scl-70 Normal/normal Normal/no Yes/yes
F/40 2009/4 10/2 ANA/Scl-70 Fibrosis/normal PAH/no Yes/no
M/26 2007/6 10/2 ANA/Scl-70 Fibrosis/normal Normal/no Yes/yes
F/21 2009/4 11/1 ANA/Scl-70 Normal/normal Normal/no Yes/no
F/30 2010/3 12/2 ANA/Scl-70 Fibrosis/normal Normal/no Yes/yes
F/33 2009/4 12/1 ANA/Scl-70 Normal/normal Normal/no Yes/no
SSc: systemic sclerosis; dcSSc: diffuse cutaneous SSc; mRSS: modified Rodnan skin score (maximum possible score = 51); HRCT: high-resolution computed
tomography; PFT: pulmonary function test; ANA: antinuclear antibodies; Scl-70: topoisomerase; PAH: pulmonary arterial hypertension. 
 Rheumatology
The Journal of on June 5, 2016 - Published by www.jrheum.orgDownloaded from 
4 The Journal of Rheumatology 2016; 43:7; doi:10.3899/jrheum.150996
Personal non-commercial use only. The Journal of Rheumatology Copyright © 2016. All rights reserved.
 Rheumatology
The Journal of on June 5, 2016 - Published by www.jrheum.orgDownloaded from 
skin (Figure 2). Further, in the LSS dcSSc skin, the number
of S100A4+/ADAM12+ FB surrounding the vessels (Figure
2, C1–2) was significantly higher when compared with EOS
dcSSc skin (Figure 2, B1–2).
TGF-β induced an increased expression of ADAM12 in MSC
and FB isolated by patients with dcSSc. Figure 3A shows that
in untreated (UT) dcSSc-MSC, the mRNA levels of
ADAM12 were significantly higher when compared with the
levels of ADAM12 expression in UT HC-MSC [ADAM12
mRNA levels in UT MSC: 2.87 (2.27–3.95) in EOS
dcSSc-MSC vs 0.98 (0.74–1.50) in HC-MSC, p < 0.0001,
and 4.06 (2.65–4.34) in LSS dcSSc-MSC vs 0.98 (0.74–1.50)
in HC-MSC, p < 0.0001]. After 10 ng/ml of TGF-β treatment
for 7 days, we saw a significant increase in ADAM12, with
the highest levels observed in dcSSc-MSC when compared
with HC-MSC. [ADAM12 mRNA levels in TGF-β–treated
MSC: 7.61 (6.23–9.56) in EOS dcSSc-MSC vs 3.42
(2.56–3.98) ADAM12 mRNA levels in HC-MSC, p <
0.0001, and 9.65 (8.36–10.43) in LSS dcSSc-MSC vs 3.42
(2.56–3.98) ADAM12 mRNA levels in HC-MSC, p <
0.0001]. No significant differences were observed in
ADAM12 expression between EOS and LSS dcSSc-MSC.
The results obtained with perivascular MSC mirrored those
observed in FB. The ADAM12 levels in UT HC-FB were
5Cipriani, et al: ADAM12 in SSc
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Figure 1. ADAM12 expression in skin of patients with dcSSc. (A1–6) IF staining of HC skin. Microphotographs A1–3 show the same section stained with
ADAM12 (green), vWF (red), and together. Microphotographs A4–6 show the same section stained with ADAM12 (green), α-SMA (red), and together. A
weak expression of ADAM12 may be observed in EC and pericytes of HC skin vessels. (B1–6) IF staining of EOS dcSSc skin. Microphotographs B1–3 show
the same section stained with ADAM12 (green), vWF (red), and together. Microphotographs B4–6 show the same section stained with ADAM12 (green), α-
SMA (red), and together. ADAM12 was strongly expressed in EC and pericytes of EOS dcSSc skin vessels. (C1–6) IF staining of LSS dcSSc skin.
Microphotographs C1–3 show the same section stained with ADAM12 (green), vWF (red), and together. Microphotographs C4–6 show the same section
stained with ADAM12 (green), α-SMA (red), and together. ADAM12 was strongly expressed in EC and pericytes of LSS dcSSc skin vessels. (D1–3) IF
staining of HC skin. Microphotographs show the same section stained with ADAM12 (green), NG2 (red), and together. A weak expression of ADAM12 may
be observed in EC and pericytes of HC skin vessels. (E1–3) IF staining of EOS dcSSc skin. Microphotographs show the same section stained with ADAM12
(green), NG2 (red), and together. ADAM12 was strongly expressed in EC and pericytes of EOS dcSSc skin vessels. (F1–3) IF staining of LSS dcSSc skin.
Microphotographs show the same section stained with ADAM12 (green), NG2 (red), and together. ADAM12 was strongly expressed in EC and pericytes of
LSS dcSSc skin vessels. (G) Densitometric analysis of the IF intensity for ADAM12. Results are expressed as median (range) of the IF intensity measured
using ImageJ. A significant increase of ADAM12 expression was observed in patients with dcSSc when compared with HC. HC vs EOS dcSSc: ** p = 0.0002.
HC vs LSS dcSSc: *** p = 0.0001. dcSSc: diffuse cutaneous systemic sclerosis; IF: immunofluorescence; vWF: von Willebrand factor; EC: endothelial cells;
HC: healthy controls; EOS: early-onset subset; LSS: longstanding subset; α-SMA: α-smooth muscle actin.
Figure 2. ADAM12 expression in perivascular FB of dcSSc skin. (A–C) IF staining of HC skin (A1–2), EOS dcSSc skin (B1–2), and LSS dcSSc skin (C1–2).
The microphotographs A1, B1, and C1 show the merger of double-staining of ADAM12 (green) and vWF (red) at 10× magnification. The areas inside the
squares are shown in microphotographs A2, B2, and C2 at 40× in the consecutive section and stained with ADAM12 (green) and S100A4 (red). The ADAM12+
perivascular cells coexpresses the FB marker S100A4. (D) Median number of S100A4+ADAM12+ cells obtained in 5 different HPF. The number of
S100A4+ADAM12+ cells was significantly higher in LSS dcSSc skin when compared to EOS dcSSc skin. Any dot plot is representative of the median cells
count per 5 HPF (40×) for each patient. HC vs EOS dcSSc: ** p = 0.0002. HC vs LSS dcSSc: ** p = 0.0002. EOS dcSSc vs LSS dcSSc: ** p = 0.0002. FB:
fibroblasts; dcSSc: diffuse cutaneous systemic sclerosis; IF: immunofluorescence; HC: healthy controls; EOS: early-onset subset; LSS: longstanding subset;
vWF: von Willebrand factor; HPF: high power fields.
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significantly lower than in dcSSc cells [ADAM12 mRNA
levels in UT FB: 8.55 (7.19–9.33) in EOS dcSSc-FB vs 0.99
(0.80–1.37) in HC-FB, p < 0.0001, and 8.73 (6.12–10.30) in
LSS dcSSc-FB vs 0.99 (0.80–1.37) in HC-FB, p < 0.0001].
In HC-FB treated with TGF-β, we observed a significant
increase of ADAM12 gene expression, and this increase was
significantly higher in dcSSc-FB [ADAM12 mRNA levels
in TGF-β–treated FB: 13.15 (11.43–18.45) in EOS dcSSc-FB
vs 5.11 (4.56–6.36) ADAM12 mRNA levels in HC-FB, p <
0.0001, and 15.50 (11.98–18.25) in LSS dcSSc-FB vs 5.11
(4.56–6.36) ADAM12 mRNA levels in HC-FB, p < 0.0001;
Figure 3B]. These results were confirmed at the protein level
by western blotting analyses (Figures 2C and 2D).
Immunolocalization of ADAM12 in dcSSc cells. Under
normal conditions, inactive ADAM12 resides mainly in the
perinuclear area, and it translocates to the cytoplasm when
activated. This process may be induced by extracellular
stimuli, such as TGF-β33,34. In UT HC-MSC, the ADAM12
immunolocalization was in perinuclear regions. After activa -
tion with TGF-β treatment, ADAM12 appeared evenly
distributed in the cytoplasm of the HC-MSC. Interestingly,
in UT dcSSc-MSC, ADAM12 was found on the cytoplasm,
suggesting its activated status (Figure 3E). Mirroring the
MSC behavior, UT dcSSc-FB displayed a cytoplasmic distri-
bution of ADAM12. In UT HC-FB, ADAM12 was expressed
in perivascular regions and TGF-β treatment induced a
cytoplasmic distribution of the molecule (Figure 3F). In both
HC-MSC and HC-FB, the expression of ADAM12 was
significantly lower when compared with dcSSc cells.
ADAM12 silencing inhibited TGF-β induction of α-SMA
expression in SSc-MSC and -FB. To inactivate ADAM12 gene
product in both dcSSc-MSC and dcSSc-FB, we transfected
the cells with ADAM12-siRNA or scrambled control siRNA
(scr-siRNA). ADAM12-siRNA efficiently knocked down
ADAM12 in both dcSSc-MSC and dcSSc-FB (> 70%).
Figures 4A and 4B show that TGF-β stimulus induced a
significant ADAM12 mRNA upregulation in both
dcSSc-MSC and dcSSc-FB treated with scr-siRNA. But
TGF-β was unable to induce ADAM12 increase in cells
treated with ADAM12-siRNA.
ADAM12 silencing blocked the ability of TGF-β to
induce α-SMA protein expression in both dcSSc-MSC and
dcSSc-FB, but in scr-siRNA–treated cells, TGF-β treatment
induced a significant upregulation of α-SMA in both
dcSSc-MSC and dcSSc-FB, as assessed by western blot
(Figures 4C and 4D).
Further, in no-target, scr-siRNA–transfected dcSSc-FB,
TGF-β treatment induced a significant upregulation of Col1A1,
α-SMA, and CTGF. However, ADAM12 silencing blocked the
ability of TGF-β to induce Col1A1, α-SMA, and CTGF gene
expression in the same cells (Figures 4E, 4F, and 4G).
DISCUSSION
Our results show that pericytes of patients with SSc express
the activated form of ADAM12 molecule, and that TGF-β,
the main profibrotic cytokine in SSc26,35,36,37,38, modulates
ADAM12 expression on these cells. These data suggest that,
as observed in other experimental models of fibrosis, perivas-
cular cells may be committed to transdifferentiate toward
activated myofibroblasts and are involved in the fibrotic
lesions of SSc.
After chronic injuries, fibrosis is the end stage in different
pathologic conditions including cardiovascular diseases,
chronic lung and kidney diseases, liver cirrhosis, and SSc39.
To understand this complex biological process, studies12
suggested a role for the discrete and poorly appreciated
populations of mesenchymal perivascular cells. These cells
have been variously named as mural cells or pericytes, and
several of their functions are largely unknown. At present,
pericytes are considered one of the most important players in
different fibrotic diseases4,40,41. Dulauroy, et al19, using
genetic studies in mice to observe neural crest cell-derived
embryonic mesenchyme, which expresses the ADAM12,
found that fetal ADAM12+ cells contribute to the generation
of perivascular cells in  adult skeletal muscle. In fact, a subset
of these cells deriving from the ADAM12+ lineage expressed
pericytes markers and wrapped-around capillaries. After
injury, the reactivation of ADAM12+ cells recapitulates an
ontogenic program aimed at restoring vascular integrity.
Under the influence of chronic stimuli, such as the persis -
tence of profibrotic cytokines and/or chronic ischemia, this
reparative mechanism may lead to an inappropriate fibrotic
outcome characterized by the detachment and migration of
ADAM12+ perivascular cells lineage to the tissue and their
transdifferentiation toward activated myofibroblast. Of note,
both the overexpression of profibrotic cytokines and the
tissue ischemia are known to play pathogenic roles during
SSc.
Our results confirm the presence of ADAM12+ cells in
the perivascular areas of the affected skin of patients with
dcSSc, and the expression of S100A4+/ADAM12+ cells in
the fibrotic skin was limited to close to the vessels in EOS
patients. Further, we showed an increased ADAM12 flores-
cence intensity in LSS patients when compared with EOS
patients, and this enhanced intensity was associated with an
increased number of S100A4+/ADAM12+ cells and with the
severity of the fibrosis. In addition, these cells in LSS patients
were widely distributed in the fibrotic area.
In a mouse treated with bleomycin, an experimental model
of SSc, it has been shown that pericytes may contribute to
skin fibrosis16. Further, we provided evidence of a profibrotic
phenotype of human perivascular cells expressing increased
levels of α-SMA and collagen during SSc3,5, and that SSc-EC
may modulate the production of profibrotic molecules in
perivascular dcSSc-MSC, thus eliciting a profibrotic pheno -
type4. The findings of ADAM12 hyperexpression and
activation in SSc perivascular cells support the hypothesis of
the profibrotic involvement of these cells during SSc.
7Cipriani, et al: ADAM12 in SSc
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Taken together, these data lead us to speculate that
perivascular cells of patients with dcSSc undergoing myofi-
broblast differentiation move from the perivascular areas to
colonize the affected tissues and contribute to the FB
recruitment and accumulation.
The functional involvement of ADAM12 in myofibroblast
generation during SSc is still a matter of debate. ADAM12
plays a direct profibrotic role, regulating TGF-β
signaling23,42,43. After TGF-β binds with specific receptors,
the signal is transduced to the nucleus by members of the
Sma- and Mad-related (Smad) family. It has been reported23,44
that, in vitro, TGF-β stimulation induces an accumulation of
ADAM12, in turn inducing Smad phosphorylation. On the
other hand, depletion of endogenous ADAM12 by siRNA
suppresses Smad phosphorylation44. In our setting, the levels
of ADAM12 were significantly higher in SSc cells when
compared with HC cells, already before the TGF-β stimu-
lation. After TGF-β treatment, a significant increase of
ADAM12 was shown in both SSc and HC cells, the highest
levels observed in the cells of patients with SSc. We may
suggest that, during SSc, a pathological environment enriched
in TGF-β may contribute to pericytes differentiation toward
8 The Journal of Rheumatology 2016; 43:7; doi:10.3899/jrheum.150996
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Figure 4. ADAM12 involvement in TGF-β–stimulated expression of myofibroblast markers. (A) dcSSc-MSC and (B) dcSSc-FB were transfected with specific
ADAM12-siRNA or non-targeting scr, and ADAM12 expression was evaluated by qRT-PCR. The cells transfected with ADAM12-siRNA showed a decreased
expression of ADAM12 gene when compared with cells transfected with scr-siRNA. The TGF-β stimulus induced a significant increase of ADAM12 expression
in both dcSSc-MSC and dcSSc-FB treated with scr-siRNA. On the contrary, in ADAM12-siRNA cells, TGF-β was unable to induce ADAM12 increase. (C)
Western blot of α-SMA. In both dcSSc-MSC and dcSSc-FB treated with scr-siRNA, TGF-β induced a significant increase of α-SMA. On the contrary, after
TGF-β stimulation, ADAM12-siRNA transfected dcSSc-MSC and dcSSc-FB did not express α-SMA protein. Pictures are representative of all experiments.
(D) Densitometry analysis. Protein bands were quantified by densitometry and the values were expressed as protein relative quantification/α-tubulin relative
quantification. ** p = 0.0002. *** p = 0.0001. (E) mRNA expressions of Col1A1, (F) α-SMA, and (G) CTGF in dcSSc-FB, transfected with specific ADAM12-
siRNA or non-targeting scr. dcSSc-FB transfected with ADAM12-siRNA did not show an increased expression of (E) Col1A1, (F) α-SMA, and (G) CTGF after
TGF-β stimulation. On the contrary, in the cells treated with scr-siRNA, TGF-β induced a significant increase of (E) Col1A1, (F) α-SMA, and (G) CTGF. Any
single dot in the figures represents the median of triplicate experiments for each patient. TGF-β: transforming growth factor-β; dcSSc: diffuse cutaneous
systemic sclerosis; MSC: mesenchymal stem cells; FB: fibroblasts; siRNA: small interfering RNA; scr: scramble siRNA; qRT-PCR: quantitative real-time
PCR; α-SMA: α-smooth muscle actin.
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myofibroblasts through ADAM12 upregulation, which acts as
a positive regulator of profibrotic TGF-β signaling.
The inactive form of ADAM12 is normally located in the
perinuclear region of the cell. After TGF-β stimulation,
ADAM12 loses its prodomain, migrating into the cytoplasm
as a mature molecule where it is catalytically active45. In our
experiments, we showed that in both HC-MSC and HC-FB,
the TGF-β treatment induced an intracellular redistribution
of ADAM12 from the perinuclear region to the cytoplasm.
But in both dcSSc-MSC and dcSSc-FB, ADAM12 was
already located in the cytoplasm, suggesting that during SSc,
the pathological environment, enriched in TGF-β, may
increase the active form of ADAM12.
In this activated status, ADAM12 may be involved in the
transdifferentiation of both MSC and FB toward myofibro -
blasts, as shown by the increased α-SMA expression. To
confirm the functional role of ADAM12 in α-SMA induction,
after ADAM12 silencing and in vitro TGF-β stimulation, we
showed that the ADAM12-silenced cells were unable to induce
α-SMA expression. Further, after ADAM12 silencing, the SSc-
FB were unresponsive to TGF-β stimulation and were enabled
to induce Col1A1, α-SMA, and CTGF gene expression.
Our results showed that not only pericytes, but also
dcSSc-EC of the dermal vessel expressed ADAM12. The
involvement of this molecule in EC is still not fully under-
stood. During the physiological angiogenesis, many metal-
loproteinases are responsible for ECM degradation to support
EC invasion46. Pathological activation of ADAM12 seems to
be associated with the dissolution of adherent junctions and
the loss of cell-cell contacts, resulting in EC apoptosis, as
reported by an in vitro study performed on EC47,48. On these
bases, we speculate that the increase of ADAM12 expression
in a dysfunctional endothelium may be associated with the
loss of cell-cell contacts, resulting in vessel rarefaction and
avascular areas, as observed in SSc.
Several studies focused on pericytes as a possible source
of the activated myofibroblasts observed during different
fibrotic conditions, including SSc. In our work, we provide
evidence of activated ADAM12 expression in SSc perivas-
cular cells, suggesting their tendency toward profibrotic
activity. Further, the evidence of S100A4+/ADAM12+ cells
located in the perivascular areas during the early phase of the
disease and widely diffused in the fibrotic areas during
longstanding disease leads us to hypothesize their possible
origin from perivascular cells that successively migrated into
the affected tissues.
Further studies analyzing the relationship between
ADAM12 and ALK5, or analyzing the inhibition of
ADAM12 functions, may support the hypothesis that
targeting ADAM12 can prevent fibrosis, a clinical pattern
still needing effective therapies.
ACKNOWLEDGMENT
The authors thank Federica Sensini for her technical assistance. 
REFERENCES
   1.    Denton CP, Black CM, Abraham DJ. Mechanisms and consequences
of fibrosis in systemic sclerosis. Nat Clin Pract Rheumatol
2006;2:134-44.
   2.    Ho YY, Lagares D, Tager AM, Kapoor M. Fibrosis—a lethal
component of systemic sclerosis. Nat Rev Rheumatol 2014;
10:390-402.
   3.    Cipriani P, Marrelli A, Benedetto PD, Liakouli V, Carubbi F,
Ruscitti P, et al. Scleroderma mesenchymal stem cells display a
different phenotype from healthy controls; implications for 
regenerative medicine. Angiogenesis 2013;16:595-607.
   4.    Cipriani P, Di Benedetto P, Ruscitti P, Campese AF, Liakouli V,
Carubbi F, et al. Impaired endothelium-mesenchymal stem cells
cross-talk in systemic sclerosis: a link between vascular and fibrotic
features. Arthritis Res Ther 2014;16:442.
   5.    Cipriani P, Di Benedetto P, Capece D, Zazzeroni F, Liakouli V,
Ruscitti P, et al. Impaired Cav-1 expression in SSc mesenchymal
cells upregulates VEGF signaling: a link between vascular
involvement and fibrosis. Fibrogenesis Tissue Repair 2014;7:13.
   6.    Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA.
Myofibroblasts and mechano-regulation of connective tissue 
remodelling. Nat Rev Mol Cell Biol 2002;3:349-63.
   7.    Ehrlich HP, Allison GM, Leggett M. The myofibroblast, cadherin,
alpha smooth muscle actin and the collagen effect. Cell Biochem
Funct 2006;24:63-70.
   8.    Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol
2008;214:199-210.
   9.    Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML,
Gabbiani G. The myofibroblast: one function, multiple origins. Am
J Pathol 2007;170:1807-16.
 10.    Ballhause TM, Soldati R, Mertens PR. Sources of myofibroblasts in
kidney fibrosis: all answers are correct, however to different extent!
Int Urol Nephrol 2014;46:659-64.
 11.    LeBleu VS, Taduri G, O’Connell J, Teng Y, Cooke VG, Woda C, et
al. Origin and function of myofibroblasts in kidney fibrosis. Nat
Med 2013;19:1047-53.
 12.    Duffield JS. The elusive source of myofibroblasts: problem solved?
Nat Med 2012;18:1178-80.
 13.    Krieg T, Abraham D, Lafyatis R. Fibrosis in connective tissue
disease: the role of the myofibroblast and fibroblast-epithelial cell
interactions. Arthritis Res Ther 2007;9 Suppl 2:S4.
 14.    Cipriani P, Di Benedetto P, Ruscitti P, Capece D, Zazzeroni F,
Liakouli V, et al. The endothelial-mesenchymal transition in
systemic sclerosis is induced by endothelin-1 and transforming
growth factor-β and may be blocked by macitentan, a dual
endothelin-1 receptor antagonist. J Rheumatol 2015;42:1808-16.
 15.    Rajkumar VS, Sundberg C, Abraham DJ, Rubin K, Black CM.
Activation of microvascular pericytes in autoimmune Raynaud’s
phenomenon and systemic sclerosis. Arthritis Rheum 1999;
42:930-41.
 16.    Liu S, Taghavi R, Leask A. Connective tissue growth factor is
induced in bleomycin-induced skin scleroderma. J Cell Commun
Signal 2010;4:25-30.
 17.    Shiwen X, Rajkumar V, Denton CP, Leask A, Abraham DJ.
Pericytes display increased CCN2 expression upon culturing. J Cell
Commun Signal 2009;3:61-4.
 18.    Ivarsson M, McWhirter A, Black CM, Rubin K. Impaired regulation
of collagen pro-alpha 1(I) mRNA and change in pattern of 
collagen-binding integrins on scleroderma fibroblasts. J Invest
Dermatol 1993;101:216-21.
 19.    Dulauroy S, Di Carlo SE, Langa F, Eberl G, Peduto L. Lineage
tracing and genetic ablation of ADAM12(+) perivascular cells
identify a major source of profibrotic cells during acute tissue
injury. Nat Med 2012;18:1262-70.
 20.    Yagami-Hiromasa T, Sato T, Kurisaki T, Kamijo K, Nabeshima Y,
9Cipriani, et al: ADAM12 in SSc
Personal non-commercial use only. The Journal of Rheumatology Copyright © 2016. All rights reserved.
 Rheumatology
The Journal of on June 5, 2016 - Published by www.jrheum.orgDownloaded from 
Fujisawa-Sehara A. A metalloprotease-disintegrin participating in
myoblast fusion. Nature 1995;377:652–6.
 21.    Gilpin BJ, Loechel F, Mattei MG, Engvall E, Albrechtsen R, Wewer
UM. A novel, secreted form of human ADAM 12 (meltrin alpha)
provokes myogenesis in vivo. J Biol Chem 1998;273:157–66.
 22.    Taniguchi T, Asano Y, Akamata K, Aozasa N, Noda S, Takahashi T,
et al. Serum levels of ADAM12-S: possible association with the
initiation and progression of dermal fibrosis and interstitial lung
disease in patients with systemic sclerosis. J Eur Acad Dermatol
Venereol 2013;27:747-53.
 23.    Le Pabic H, Bonnier D, Wewer UM, Coutand A, Musso O, Baffet G,
et al. ADAM12 in human liver cancers: TGF-beta-regulated
expression in stellate cells is associated with matrix remodeling.
Hepatology 2003;37:1056–66.
 24.    Shi-Wen X, Renzoni EA, Kennedy L, Howat S, Chen Y, Pearson JD,
et al. Endogenous endothelin-1 signaling contributes to type I
collagen and CCN2 overexpression in fibrotic fibroblasts. Matrix
Biol 2007;26:625–32.
 25.    Skubitz KM, Skubitz AP. Gene expression in aggressive 
fibromatosis. J Lab Clin Med 2004;143:89–98.
 26.    Lafyatis R. Transforming growth factor β—at the centre of systemic
sclerosis. Nat Rev Rheumatol 2014;10:706-19.
 27.    Cai X, Lin Y, Friedrich CC, Neville C, Pomerantseva I, Sundback
CA, et al. Bone marrow derived pluripotent cells are pericytes
which contribute to vascularization. Stem Cell Rev 2009;5:437–45.
 28.    Bianco P, Riminucci M, Gronthos S, Robey PG. Bone marrow
stromal stem cells: nature, biology, and potential applications. Stem
Cells 2001;19:180–92.
 29.    LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger
TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets
and pathogenesis. J Rheumatol 1988;15:202-5.
 30.    van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M,
Tyndall A, et al. 2013 Classification criteria for systemic sclerosis:
an American College of Rheumatology/European League Against
Rheumatism collaborative initiative. Ann Rheum Dis 2013;
72:1747-55.
 31.    Kahaleh MB, Sultany GL, Smith EA, Huffstutter JE, Loadholt CB,
LeRoy EC. A modified scleroderma skin scoring method. Clin Exp
Rheumatol 1986;4:367–9.
 32.    Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire
G, et al. Autoantibodies and microvascular damage are independent
predictive factors for the progression of Raynaud’s phenomenon to
systemic sclerosis: a twenty-year prospective study of 586 patients,
with validation of proposed criteria for early systemic sclerosis.
Arthritis Rheum 2008;58:3902-12.
 33.    Cao Y, Kang Q, Zhao Z, Zolkiewska A. Intracellular processing of
metalloprotease disintegrin ADAM12. J Biol Chem
2002;277:26403-11.
 34.    Stautz D, Sanjay A, Hansen MT, Albrechtsen R, Wewer UM,
Kveiborg M. ADAM12 localizes with c-Src to actin-rich structures
at the cell periphery and regulates Src kinase activity. Exp Cell Res
2010;316:55-67.
 35.    Wan YN, Wang YJ, Yan JW, Li XP, Tao JH, Wang BX, et al. The
effect of TGF-β1 polymorphism on systemic sclerosis: a systematic
review and pooled analysis of available literature. Rheumatol Int
2013;33:2859-65.
 36.    Hatton N, Frech T, Smith B, Sawitzke A, Scholand MB, Markewitz
B. Transforming growth factor signalling: a common pathway in
pulmonary arterial hypertension and systemic sclerosis. Int J Clin
Pract Suppl 2011;172:35-43.
 37.    Liakouli V, Cipriani P, Marrelli A, Alvaro S, Ruscitti P, Giacomelli
R. Angiogenic cytokines and growth factors in systemic sclerosis.
Autoimmun Rev 2011;10:590-4.
 38.    Rice LM, Padilla CM, McLaughlin SR, Mathes A, Ziemek J,
Goummih S, et al. Fresolimumab treatment decreases biomarkers
and improves clinical symptoms in systemic sclerosis patients. 
J Clin Invest 2015;125:2795-807. 
 39.    Wynn TA. Common and unique mechanisms regulate fibrosis in
various fibroproliferative diseases. J Clin Invest 2007;117:524-9.
 40.    Sato M, Suzuki S, Senoo H. Hepatic stellate cells: unique 
characteristics in cell biology and phenotype. Cell Struct Funct
2003;28:105-12.
 41.    Lin SL, Kisseleva T, Brenner DA, Duffield JS. Pericytes and
perivascular fibroblasts are the primary source of 
collagen-producing cells in obstructive fibrosis of the kidney. Am J
Pathol 2008;173:1617-27.
 42.    Ray A, Dhar S, Ray BK. Transforming growth factor-beta1-mediated
activation of NF-kappaB contributes to enhanced ADAM-12
expression in mammary carcinoma cells. Mol Cancer Res
2010;8:1261-70.
 43.    Kim YM, Kim J, Heo SC, Shin SH, Do EK, Suh DS, et al.
Proteomic identification of ADAM12 as a regulator for 
TGF-β1-induced differentiation of human mesenchymal stem cells
to smooth muscle cells. PLoS One 2012;7:e40820.
 44.    Atfi A, Dumont E, Colland F, Bonnier D, L’helgoualc’h A, Prunier
C, et al. The disintegrin and metalloproteinase ADAM12 contributes
to TGF-beta signaling through interaction with the type II receptor. 
J Cell Biol 2007;178:201-8.
 45.    Loechel F, Gilpin BJ, Engvall E, Albrechtsen R, Wewer UM.
Human ADAM 12 (meltrin alpha) is an active metalloprotease. 
J Biol Chem 1998;273:16993-7.
 46.    Roy R, Zhang B, Moses MA. Making the cut: protease-mediated
regulation of angiogenesis. Exp Cell Res 2006;312:608-22.
 47.    Herren B, Levkau B, Raines EW, Ross R. Cleavage of beta-catenin
and plakoglobin and shedding of VE-cadherin during endothelial
apoptosis: evidence for a role for caspases and metalloproteinases.
Mol Biol Cell 1998;9:1589–601.
 48.    Ponnuchamy B, Khalil RA. Role of ADAMs in endothelial cell
permeability: cadherin shedding and leukocyte rolling. Circ Res
2008;102:1139-42.
10 The Journal of Rheumatology 2016; 43:7; doi:10.3899/jrheum.150996
Personal non-commercial use only. The Journal of Rheumatology Copyright © 2016. All rights reserved.
 Rheumatology
The Journal of on June 5, 2016 - Published by www.jrheum.orgDownloaded from 
